Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

C4 THERAPEUTICS, INC.

(CCCC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about C4 THERAPEUTICS, INC.
11/23BofA Securities Starts C4 Therapeutics at Buy With $54 Price Target
MT
11/10C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Res..
PU
11/10C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Res..
GL
10/28BRD9 TPD Summit Presentation
PU
10/28CFT8919 TPD Summit Presentation
PU
10/14C4 THERAPEUTICS : SVB Leerink Starts C4 Therapeutics at Outperform with $67 Price Target
MT
10/05INSIDER SELL : C4 Therapeutics
MT
09/30C4 THERAPEUTICS : Stifel Starts C4 Therapeutics at Hold With $45 Price Target
MT
09/24INSIDER SELL : C4 Therapeutics
MT
09/22INSIDER SELL : C4 Therapeutics
MT
09/17INSIDER SELL : C4 Therapeutics
MT
09/15Certain Common Stock of C4 Therapeutics, Inc. are subject to a Lock-Up Agreement Ending..
CI
09/15Certain Stock Options of C4 Therapeutics, Inc. are subject to a Lock-Up Agreement Endin..
CI
09/14INSIDER SELL : C4 Therapeutics
MT
08/12C4 THERAPEUTICS' : Q2 Loss Narrows, Revenue Grows; Secures Orphan Drug Designation for Mul..
MT
08/11C4 THERAPEUTICS : Dosed First Patient in Phase 1/2 Clinical Trial of CFT7455, a novel IKZF..
PU
08/11C4 THERAPEUTICS : Reports Recent Business Highlights and Second Quarter 2021 Financial Res..
AQ
08/11C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of ..
GL
08/11C4 Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Qu..
CI
08/11C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of ..
CI
08/11C4 Therapeutics Says CFT7455 Gets Orphan Drug Designation for Multiple Myeloma
DJ
06/25C4 THERAPEUTICS, INC.(NASDAQGS : CCCC) dropped from Russell 2000 Value Index
CI
06/25C4 THERAPEUTICS, INC.(NASDAQGS : CCCC) dropped from Russell 2500 Value Index
CI
06/25C4 THERAPEUTICS, INC.(NASDAQGS : CCCC) dropped from Russell 3000E Value Index
CI
06/25C4 THERAPEUTICS, INC.(NASDAQGS : CCCC) dropped from Russell 3000 Value Index
CI
06/25C4 THERAPEUTICS, INC.(NASDAQGS : CCCC) dropped from Russell Small Cap Comp Value Index
CI
06/24C4 THERAPEUTICS : Brookline Initiates Coverage on C4 Therapeutics With Buy Rating, $54 Pri..
MT
06/22C4 THERAPEUTICS : BMO Capital Adjusts C4 Therapeutics' Price Target to $53 From $55, Keeps..
MT
06/21C4 THERAPEUTICS : Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the ..
PU
06/21C4 Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underw..
GL
06/21C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the..
GL
06/21C4 Therapeutics, Inc. Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader f..
CI
06/17C4 THERAPEUTICS : Prices Common Stock Offering at $37 Per Share
MT
06/16C4 Therapeutics Announces Pricing of Public Offering
GL
06/15UPDATE : C4 Therapeutics Starts 4.25 Million Shares Offering -- Stock Down 10% in Afternoo..
MT
06/14C4 Therapeutics Starts 4.25 Million Shares Offering -- Stock Down 4% After-Hours
MT
06/14C4 THERAPEUTICS : Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT..
PU
06/14C4 Therapeutics Launches Proposed Public Offering
GL
06/14C4 THERAPEUTICS : Doses First Patient in Study of Potential Multiple Myeloma, Non-Hodgkin'..
MT
06/14C4 THERAPEUTICS : Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT..
AQ
06/14C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CF..
CI
06/07C4 THERAPEUTICS : Pre-clinical Data Support Plans to Advance CFT8919 to Clinical Developme..
PU
06/07C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L85..
GL
06/07C4 Therapeutics, Inc. Presents Pre-Clinical Data on CFT8919
CI
06/07C4 THERAPEUTICS : CFT8919 Pre-Clinical Data
PU
06/04C4 THERAPEUTICS : HC Wainwright Starts C4 Therapeutics at Buy With $63 Price Target
MT
05/26C4 THERAPEUTICS : CFT8919 Pre-clinical Data on EGFR L858R-driven NSCLC to be Presented at ..
PU
05/26C4 THERAPEUTICS : Plans to Pursue IND-Enabling Studies for Lung Cancer Drug
MT
05/26C4 Therapeutics to Advance CFT8919, A Selective Degrader of EGFR L858R, Into IND-enabli..
GL
05/26C4 Therapeutics, Inc. to Advance CFT8919, A Selective Degrader of EGFR L858R, Into IND-..
CI
05/20C4 THERAPEUTICS : Brings in Novartis Executive as New CFO
MT
05/20C4 Therapeutics Appoints Lauren White as Chief Financial Officer
GL
05/20C4 Therapeutics, Inc. Changes in Chief Financial Officer, Effective June 21, 2021
CI
05/13C4 THERAPEUTICS : Reports Recent Business Highlights and First Quarter 2021 Financial Resu..
AQ
05/13C4 Therapeutics Reports Consolidated Earnings Results for the Three Months Ended March ..
CI
05/12C4 Therapeutics to Present at Upcoming Investor Conferences
GL
04/30Laura J. Wahlberg to Resign from C4 Therapeutics, Inc. as Vice President, Finance, Corp..
CI
04/10C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader for the ..
GL
04/10C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader for the ..
CI
03/31C4 THERAPEUTICS : BMO Capital Starts C4 Therapeutics at Outperform With $55 Price Target
MT
03/31Certain Common Stock of C4 Therapeutics, Inc. are subject to a Lock-Up Agreement Ending..
CI
03/31Certain Options of C4 Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 3..
CI
03/31Certain Warrants of C4 Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on ..
CI
03/21C4 THERAPEUTICS, INC.(NASDAQGS : CCCC) added to S&P Global BMI Index
CI
03/21C4 THERAPEUTICS, INC.(NASDAQGS : CCCC) added to S&P Biotechnology Select Industry Index
CI
03/11C4 Therapeutics, Inc. Elects Glenn Dubin as A Director
CI
03/11C4 Therapeutics Reports Recent Business Highlights and Full Year 2020 Financial Results
GL
03/11C4 Therapeutics Reports Consolidated Earnings Results for the Full Year Ended December ..
CI
03/10C4 Therapeutics to Present on the Discovery and Preclinical Development of CFT7455, a M..
GL
02/26C4 THERAPEUTICS : UBS Adjusts C4 Therapeutics' Price Target to $60 From $44, Keeps Buy Rat..
MT
02/24C4 Therapeutics to Participate in Upcoming March Investor Conferences
GL
02/11C4 Therapeutics to Participate in BMO BioPharma Spotlight Series
GL
01/19C4 THERAPEUTICS' : Investigational New Drug Application for CFT7455 to Treat Blood Disease..
MT
01/19C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT..
GL
01/19C4 Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application f..
CI
1  2Next
Upcoming sector events